3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
It's not always a good idea to chase trends in a bull market, but sometimes the new wave of promising companies is more than a fad. In the biotech and pharma industries, right now is an exciting time, and there's reason to believe that the popular players of today will be strong investments for more than just a few months.
There are three companies in particular that you should know about, so let's cover each one below.
Vertex Pharmaceuticals (NASDAQ: VRTX) has a few different drivers that could power it to success during this bull market. First, there's the ongoing launch of its gene therapy Casgevy, which is a cure or near-cure for sickle cell disease (SCD) and beta thalassemia, a pair of rare hereditary disorders of the blood. That's a part of why analysts are expecting the company to bring in an average of $10.7 billion in sales this year.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Die Vertex Pharmaceuticals Inc. Aktie zieht viel Aufmerksamkeit auf sich: Viel mehr Buy- als Sell-Einschätzungen.
Ein Kursziel von 440 € für Vertex Pharmaceuticals Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 422.25 €.
